Inimmune

Executive Summary

Inimmune is a private biopharmaceutical company headquartered in Missoula, Montana, focused on harnessing the immune system to develop novel therapies for infectious diseases, cancer, and autoimmune disorders. Founded in 2016, the company specializes in Toll-like receptor (TLR) agonists, a class of small molecules that modulate innate immunity. Its lead program, INI-4001, is a TLR4 agonist designed as an intranasal vaccine adjuvant, currently in Phase 2 clinical trials for respiratory infections. Additionally, INI-2001, a TLR7/8 agonist, is being evaluated for cancer immunotherapy. Inimmune's platform technology enables targeted immune activation with potential applications across multiple therapeutic areas, including pandemic preparedness and oncology. The company has demonstrated preclinical efficacy in enhancing vaccine responses and anti-tumor immunity, positioning it as a key player in the immune modulation space. Despite limited public financial disclosures, Inimmune's Phase 2 stage and proprietary pipeline suggest significant upside if clinical data continue to support safety and efficacy.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Data Readout for INI-4001 as Intranasal Vaccine Adjuvant45% success
• Q4 2026Partnership or Licensing Deal for INI-2001 in Cancer Immunotherapy50% success
• H1 2027IND Filing for New TLR Agonist Candidate60% success